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ASSOCIATION BETWEEN ALCOHOL USE BEHAVIOR AND 
LIVER FAT IN THE FRAMINGHAM HEART STUDY 
MICHELLE T. LONG 
ABSTRACT 
Many individuals presumed to have non-alcoholic fatty liver disease (NAFLD) consume 
moderate amounts of alcohol; however, little is known regarding patterns of alcohol use 
and how drinking behaviors may influence liver fat. We conducted a cross-sectional 
study of 2,475 participants of the Framingham Heart Study who underwent computed 
tomography (CT) to define liver fat. We performed multivariable-adjusted logistic 
regression models for the association between different alcohol drinking patterns, 
including the average alcoholic drinks/week, frequency of alcohol use, usual quantity of 
alcohol consumed, maximum drinks consumed in 24 hours, and binge drinking behavior, 
and CT-defined hepatic steatosis. We excluded heavy alcohol users defined as women 
who drink > 14 drinks/week and men who drink > 21 drinks/week. We also performed an 
analysis specific to beverage type (beer, wine, or liquor/spirit drinks).The prevalence of 
hepatic steatosis in our study sample (mean age ± standard deviation (SD) 49.8±10.2, 
50.3% women) was 17.5%. Among individuals with presumed NAFLD, binge drinking 
occurred in 25.4% of individuals. In adjusted models, the odds of hepatic steatosis 
increased by 20% for each SD increase in the number of alcoholic drinks consumed per 
week (OR 1.20; 95% confidence interval (CI) 1.08, 1.36). Frequency of alcohol use 
(drinking days/week) was also associated with hepatic steatosis (OR 1.09; 95% CI 1.03, 
1.15). The odds of hepatic steatosis increased by 15% for each SD increase in the 
	
	 vi 
maximum drinks per week (OR 1.15; 95% CI 1.02, 1.30). In the beverage specific 
analysis, alcohol use patterns were associated with hepatic steatosis among beer drinkers, 
but no significant associations were observed among wine drinkers. Conclusions: Even 
after excluding heavy alcohol users from our sample, alcohol use contributed to liver fat, 
which suggests alcohol-related liver fat may be present among individuals presumed to 
have NAFLD. Additional prospective studies are needed to validate our findings and to 
determine if more comprehensive alcohol use screening tools should be used in practice 
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Non-alcoholic fatty liver disease (NAFLD), which is characterized by the presence of 
hepatic steatosis in the absence of secondary causes, is the most common cause of 
chronic liver disease worldwide.1 Pathologically, NAFLD and alcoholic liver disease 
(ALD) appear identical and the only distinguishing feature is the presence or absence of 
significant alcohol exposure. The association of alcohol consumption and NAFLD is 
controversial, as the findings in the literature are mixed. Multiple studies have reported a 
beneficial effect of modest alcohol consumption in NAFLD2-6; however, other studies 
have reported detrimental effects7-13. The extent to which these discrepant results may be 
attributed to different alcohol consumption patterns in different study populations, even 
with similar average daily consumption, is not known. There are many confounding 
factors to consider as well. Those with chronic diseases may be more likely to abstain 
from alcohol so the presence of co-existing metabolic disease may not only influence the 
pattern of alcohol use but also confound any protective effect of modest alcohol use.  
Recent evidence suggests that the pattern of alcohol consumption may be an 
important predictor of the health effects of alcohol14. However, most of the studies 
evaluating alcohol use among individuals with NAFLD focus instead on average daily or 
weekly alcohol consumption, which will obscure differences in drinking frequency, usual 
quantity consumed, and binge drinking behavior. Currently the American Association for 
the Study of Liver Disease guidelines lack details regarding recommendations for the 
pattern of drinking in NAFLD. Additionally, little is known regarding prior alcohol 




focus on alcohol use in general and have not addressed any association between NAFLD 
and specific beverage types, after accounting for confounding factors associated with 
beverage preference.  
Thus, in this study we examined the association between different alcohol drinking 
patterns and liver fat defined on multi-detector computed tomography (MDCT), among 
participants of the Framingham Heart Study, after excluding heavy alcohol users (defined 
as women who drink > 14 drinks per week and men who drink > 21 drinks per week15). 
We evaluated for effect modification between alcohol consumption patterns and age and 
sex in relation to liver fat. We also evaluated if metabolic syndrome was a potential 
mediator on the causal pathway between alcohol and liver fat. Finally, we determined if 
any association between alcohol use pattern and liver fat differs by type of alcohol 





DESIGN AND METHODS 
Study design and participants  
 We conducted a cross-sectional, secondary analysis in the Framingham Heart 
Study (FHS). The FHS is a large, multi-generational, community cohort established in 
1948 to prospectively identify risk factors for cardiovascular disease.16 The design of the 
FHS Offspring and Third Generation Cohorts has been previously described.17,18 The 
study sample was drawn from participants in the Offspring Cohort and Third Generation 
Cohorts who participated in the MDCT sub-study to evaluate adipose tissue deposits 
between 2002 and 2005. For the Offspring Cohort participants, the closest examination 
period where alcohol use behavior was assessed was the seventh examination (1998–
2001). All covariates were drawn from the seventh examination visit with the exception 
of income data which was drawn from the third examination visit when the Offspring 
participants were in prime working age and education data which was drawn from the 
second examination visit. For the Third Generation Cohort participants, alcohol use 
behavior and all covariates were assessed at the first examination visit conducted between 
2002 and 2005 contemporaneously with the MDCT sub-study. The MDCT sub-study was 
approved by the institutional review boards of Boston University School of Medicine and 






Independent variables: Alcohol use behaviors 
We defined a number of exposures to measure various alcohol use behaviors. Average 
alcohol consumption was defined as the number of alcoholic beverages of any type 
consumed per week as derived from the physician-directed questionnaire at the index 
examination. Alcohol use frequency was assessed by asking: “Over the past year, on 
average, on how many days per week did you drink an alcoholic beverage of any type?” 
for Third Generation participants. Offspring participants were asked the average number 
of days per week they drank either beer, red wine, white wine, or liquor. We considered 
the most number of drinking days of any beverage type as the drinking frequency. Usual 
quantity consumed was assessed by asking: “Over the past year, on a typical day when 
you drink, how many drinks do you have” for Third Generation participants only (not 
asked in Offspring participants). Women who consumed more than one drink/drinking 
day and men who consumed more than two drinks per drinking day were classified as 
drinking in excess of the U.S. dietary guidelines.19 Maximum drinks in last month was 
assessed by asking: “what was the maximum number of drinks you had in a 24 hour 
period during the past month” for the Third Generation participants. Offspring 
participants were asked their usual maximum limit of alcohol by alcohol type. We 
considered the maximum drinks as the highest maximal limit of alcohol across beverage 
types. For Third Generation participants we defined binge drinking as drinking 4 or 
more (for women) or 5 or more (for men) alcoholic beverages in a 24-hour period in the 
last month or answering yes to the question “since your last exam, has there been a time 




participants, binge drinking was defined as a maximum limit of 4 or more drinks for 
women or 5 or more drinks for men. Responses were grouped into 2 categories (no vs yes 
binge drinking). Non-drinkers were divided into former drinkers and never drinkers. For 
Third Generation participants, former drinkers were identified with the question “at what 
age did you stop drinking” and any participant that reported an age less than the current 
age was considered a former drinker. For Offspring participants, we identified former 
drinkers as any participant who reported consuming at least 1 drink/week on any prior 
exam (exam 1-6). For a secondary analysis, we considered the specific type of alcoholic 
beverage consumed, specifically wine, beer, liquor/spirit drink use, or combinations 
thereof.  
 
Dependent variables: liver fat measures 
The primary dependent variable was hepatic steatosis, defined on MDCT scan. The 
MDCT scan cohort and protocol are described in detail elsewhere.20-22 In brief, 25 
contiguous 5-mm-thick slices (120 kVp, 400mA, gantry rotation time 500 ms, and table 
feed 3:1) in the abdominal region (covering 125 mm above S1) were obtained from 
participants in the supine position using an 8-slice CT scanner (LightSpeed Ultra, 
General Electric, Milwaukee, WI). A calibration phantom (Image Analysis, Lexington, 
KY) was placed under each participant and present for all images obtained. Liver 
attenuation in Hounsfield Units was measured in three areas from the liver and from the 
external phantom and averaged to compute the LPR. We defined hepatic steatosis as a 




specificity of 98% for determining significant steatosis using a liver spleen ratio < 1.1 as 
the gold standard cut-off.20 As a secondary dependent variable we considered the LPR 
as a continuous variable and modeled more liver fat as a decreasing LPR.  
 
Covariates 
Covariates were measured at the seventh examination for Offspring Cohort participants 
(1998–2001) and the first examination for Third Generation Cohort participants (2002–
2005), unless otherwise noted. Routine medical history, physical examination, and 
laboratory evaluations are performed at each FHS examination. Primary covariates 
include age, sex, cohort (Offspring vs Third Generation), current smoking, physical 
activity, education, and income. Participants were considered current smokers if they had 
smoked at least one cigarette per day in the year preceding the FHS examination. 
Physical activity was measured by the physical activity index score.23 Education was 
assessed as a categorical variable (<12 years, high school graduate, some college, college 
graduate, or graduate degree). For Offspring Cohort participants, education was assessed 
at the second examination visit (1979–1983). Income was measured as a categorical 
variable of household income/year. For Offspring Cohort participants, income data was 
obtained from the third examination (1983–1987) and adjusted for inflation to 2003 
(correction factor of 71%). Offspring Cohort participants were at a mean age of 48 years 
when income information was collected which is similar to the age of the Third 





Secondary covariates included body mass index (BMI), the metabolic syndrome, and 
the components thereof. Trained technicians used standard protocols for measuring heart 
rate, blood pressure, height, weight, and waist circumference at the examination visits. 
BMI was defined as weight (kg)/height2 (m2). Obesity was defined as a BMI ≥ 30 kg/m2. 
For the metabolic syndrome, we used the individual components separately or, 
alternatively, as a single dichotomized variable (metabolic syndrome yes vs no). Waist 
circumference was measured in inches. Serum total and high density lipoprotein 
cholesterol (HDL-c), triglycerides and glucose were measured on fasting morning blood 
samples.24 Low HDL-c was defined as <50 mg/dL for women and <40 mg/dL for men. 
Elevated triglycerides was defined as triglycerides ≥150 mg/dL. Elevated blood pressure 
was defined as a systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥ 90 mm 
Hg, or the use of anti-hypertensive medication. Impaired fasting glucose was defined as a 
fasting glucose ≥110mg/dL or treatment with a hypoglycemic agent or insulin. Metabolic 
syndrome was defined based on the description of Modified National Cholesterol 
Education Program Adult Treatment Panel III guidelines.25 The diagnosis of the 
metabolic syndrome was be made when three or more of the following cardiometabolic 
risk factors were present: 1) waist circumference >88 cm for women and >102 cm for 
men, 2) triglycerides ≥150 mg/dL, 3) HDL-c <50 mg/dL for women and <40 mg/dL for 
men, 4) systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or 
the use of anti-hypertensive medication, and 5) fasting glucose ≥110mg/dL or treatment 




ANALYSIS AND STATISTICAL METHODS 
The analysis was done using SAS 9.4 (SAS Institute, Cary, NC). All statistical tests were 
performed using a two-sided significance level of alpha = 0.05.  
We used descriptive statistics to describe participants’ characteristics, including 
demographics, anthropometrics, exposures, and covariates. Continuous variables were 
presented as mean and standard deviation. Categorical variables were expressed as 
percentage and frequencies of participants in each category.  
For the primary analysis, we used logistic regression models to obtain multivariable-
adjusted odds ratios (OR) for the association between various drinking patterns and 
hepatic steatosis (defined by the dichotomous LPR ≤ 0.33). We modeled the ORs per 
standard deviation (SD) increase in the continuous exposure. In model 1, we accounted 
for the primary covariates, including age, sex, cohort, smoking, physical activity, 
education, and income. We also considered metabolic syndrome as a potential mediator 
to the relationship between alcohol use patterns and hepatic steatosis. We tested for an 
indirect effect of metabolic syndrome by separately adjusting for BMI and metabolic 
syndrome in additional models. In Model 2, we added adjustment for BMI and the 
components of the metabolic syndrome (waist circumference, low HDL-c, high 
triglycerides, elevated blood pressure, or impaired fasting glucose) to Model 1. In Model 
3, we added adjustment for BMI and dichotomous metabolic syndrome to Model 1.  
We performed a number of pre-specified secondary analyses. First, we repeated the 
primary analysis after excluding non-drinkers, recognizing that non-drinkers represent a 




beverage specific secondary analysis by repeated the primary analysis among those that 
drink primarily beer, wine, or liquor/spirits. Finally, we considered our dependent 
variable as continuous variable (continuous LPR). We used linear regression to measure 
the multivariable-adjusted β for the association between various drinking patterns and 
negative LPR (as liver fat increases as LPR decreases). We modeled the β per SD 
increase in the continuous exposure. We performed covariate adjustment according to 
Models 1-3 as in the primary analysis.  
We evaluated for effect modification by age and sex in the primary analysis. We 
tested for effect modification by creating appropriate dummy variables representing the 
interaction effect.  
We conducted a sensitivity analysis by limiting the sample to Third Generation 
Cohort participants and repeating the primary analysis. The Third Generation Cohort 
participants had the alcohol use assessment, liver fat measurements, and covariates 






 Our sample was derived from 3,180 Offspring and Third Generation Cohort 
participants who had measurement of liver attenuation on multi-detector CT scan. We 
excluded individuals with missing alcohol use data or significant alcohol use defined as > 
14 drinks per week for women and > 21 drinks per week for men (143 participants)15, 
missing covariate data including smoking status, metabolic syndrome components, and 
physical activity (157 participants), missing education data (116 participants), or missing 
income data (287) which yielded a sample size of 2,475 participants. Most of the 
participants missing income or education data were in the Offspring cohort so the mean 
age of the participants with missing data was higher compared to those without missing 
data (A.1). For the analysis among current drinkers, we additionally excluded 473 former 
or never drinkers. For the beverage specific analysis, we excluded non-drinking 
participants or participants with mixed beverage type (total n=1633). 
Characteristics of the study sample (mean age ± SD 49.8±10.2, 50.3% women) are 
presented in Table 1. A total of 433 participants, 17.5% of the sample, had hepatic 
steatosis. Compared to those without hepatic steatosis, participants with hepatic steatosis 
were more often men, had a lower proportion reporting the top income and education 
categories, and had a higher BMI and prevalence of the metabolic syndrome or the 





Table 1: Characteristics of Study Sample, by hepatic steatosis 






Age (years) ± SD 51.2±10.2 49.5±10.1 49.8±10.2 
Women, n (%)  177 (40.9%) 1068 (52.3%) 1245 (50.3%) 
Third Generation, n (%)   275 (63.5%) 1412 (69.2%) 1687 (68.2%) 
Current smoking use, n (%) 49 (11.3%) 237 (11.6%) 286 (11.6%) 
Physical activity index ± SD 37.0±7.2 37.6±7.2 37.5±7.2 
Education, n (%)    
    Some high school 8 (1.9%) 29 (1.4%) 37 (1.5%) 
    High school graduate 103 (23.8%) 399 (19.5%) 502 (20.3%) 
       Some college 146 (33.7%) 609 (29.8%) 755 (30.5%) 
    College graduate  99 (22.9%) 594 (29.1%) 693 (28%) 
    Graduate degree 77 (17.8%) 411 (20.1%) 488 (19.7%) 
Income*, n (%)    
    <$12,000/yr 7 (1.6%) 16 (0.8%) 23 (0.9%) 
    $12,000-24,999/yr 13 (3.0%) 63 (3.1%) 76 (3.1%) 
    $25,000-49,999/yr  81 (18.7%) 373 (18.3%) 454 (18.3%) 
    $50,000-74,999/yr 111 (25.6%) 450 (22.0%) 561 (22.7%) 
    $75,000-100,000/yr 93 (21.5%) 472 (23.1%) 565 (22.8%) 
     >$100,000/yr 128 (29.6%) 668 (32.7%) 796 (32.2%) 
BMI (kg/m2) ± SD 31.2±5.7 26.6±4.8 27.4±5.3 
Waist circumference (inches) ± SD 41.8±5.6 38. ±5.3 37.8±5.6 
Low HDL cholesterol, n (%) 210 (48.5%) 524 (25.7%) 734 (29.7%) 
High Triglycerides, n (%) 221 (51.0%) 419 (20.5%) 640 (25.9%) 
Elevated blood pressure, n (%) 195 (45.0%) 479 (23.5%) 674 (27.2%) 
Impaired Fasting glucose, n (%) 113 (26.1%) 173 (8.5%) 286 (11.6%) 
Metabolic syndrome**, n (%) 214 (49.4%) 302 (14.8%) 516 (20.9%) 
Liver phantom ratio ± SD 0.27±0.06 0.37±0.02 0.36±0.05 
Alcohol use patterns    
Alcohol drinks/week ± SD 4.5±5.4 4.0±4.5 4.1±4.7 
Frequency of drinking (#drinking 
days/wk) 2.2±2.4 2.1±2.1 2.1±2.2 
Usual quantity consumed 
(drinks/drinking days)**** 1.9±1.4 1.7±1.3 1.7±1.3 
Maximum drinks ± SD 2.6±3.0 2.4±2.5 2.4±2.6 
Binge drinking, n (%) 110 (25.4%) 467 (22.9%) 577 (23.3%) 
Non-drinkers, n (%)    
     Never drinkers 16 (3.7%) 42 (2.1%) 58 (2.3%) 
     Former drinkers 81 (18.7%) 334 (16.4%) 415 (16.8%) 
 Primary beverage consumed, n (%)     




        Wine 123 (28.4%) 686 (33.6%) 809 (32.7%) 
        Liquor/Spirits 59 (13.6%) 190 (9.3%) 249 (10.1%) 
        Beer and wine 13 (3.0%) 99 (4.9%) 112 (4.5%) 
      Liquor/Spirits and beer or wine 10 (2.3%) 84 (4.1%) 94 (3.8%) 
        Non-drinker or unk 126 (29.1%) 510 (25.0%) 636 (25.7%) 
Data are expressed as mean ± standard deviation or number (percentage) unless otherwise 
noted. BMI: body mass index 
*Income indexed to 2003 dollars 
**Metabolic syndrome defined by ATP III guidelines 
***Hepatic steatosis defined as LPR ≤ 0.33 
****Third Generation Participants only 
 
Alcohol use patterns among participants with hepatic steatosis are depicted in the 
Figure. High frequency drinking (>4 drinking days per week) and binge drinking were 
common, particularly among men and drinking in excess of the US guidelines for usual 
consumption was common among both women and men.  
 
Figure 1: Prevalence of alcohol consumption patterns among participants with 
presumed NAFLD (n=433). High frequency drinking was defined as >4 drinking days 
per week). Usual consumption above US guidelines was defined as >1 drink/drinking day 
for women or >2 drinks/drinking day for men. Binge drinking was defined as > 4 drinks 




Multivariable-adjusted regression models for the association between various drinking 
patterns and hepatic steatosis (dichotomous LPR) 
We observed associations between multiple drinking patterns and hepatic steatosis 
(Table 2). In adjusted models, the odds of hepatic steatosis increased by 20% for each 
SD increase in the number of alcoholic drinks consumed per week (Model 2: OR 1.20; 
95% confidence interval (CI) 1.08, 1.36). Frequency of alcohol use (drinking days/week) 
was also associated with hepatic steatosis (Model 2: OR 1.09; 95% CI 1.03, 1.15). The 
odds of hepatic steatosis increased by 15% for each SD increase in the maximum drinks 
per week and this association was similar in both Models 2 and 3 (Model 2 OR 1.15 
(95% CI 1.02, 1.30) vs Model 3 OR 1.14 (95% CI 1.01, 1.28)). There was no association 
between the other drinking patterns evaluated and hepatic steatosis. In general, the ORs 
increased in models adjusted for BMI and metabolic syndrome components or 
dichotomous metabolic syndrome, which suggests that BMI and metabolic syndrome are 
confounding variables and do not mediate the relationship between alcohol use behavior 
and hepatic steatosis. 
When excluding non-drinkers from the analysis, the associations between alcohol 
drinks per week, frequency of alcohol use, and maximum drinks in 24 hours and hepatic 
steatosis became stronger (Table 2). We additionally observed an association between 
binge drinking and hepatic steatosis among drinkers; however, this association was 




We did not observe evidence of effect modification by age or sex. Overall, results were 
similar when we considered continuous LPR as the dependent variable though maximum 




 Overall (n=2475) Drinkers only (n=2002) 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Alcohol use pattern* OR, 95% CI, p value 
OR, 95% CI, p 
value 
OR, 95% CI, p 
value 
OR, 95% CI, 
p value 
OR, 95% CI, 
p value 
OR, 95% CI, p 
value 
Alcohol drinks per 
week  
1.09 (0.98, 1.21); 
0.10 
1.20 (1.08, 1.36); 
0.001 










1.02 (0.97, 1.07); 
0.40 
1.09 (1.03, 1.15); 
0.003 






1.11 (1.05, 1.18); 
<0.001 
Usual quantify (number 
drinks /drinking day) 
1.05 (0.96, 1.15); 
0.31 
1.02 (0.92, 1.13); 
0.75 






1.03 (0.90, 1.18); 
0.67 
Max drinks in 24 hours 1.13 (1.01, 1.27);0.03 
1.15 (1.02, 1.30); 
0.02 






1.15 (1.01, 1.32); 
0.03 
Binge drinking       
  No reference reference reference reference reference reference 









1.31 (0.96, 1.80); 
0.09 
Non-drinkers       
  Never drinkers reference reference reference    




0.10    
Table 2: Multivariable-adjusted logistic regression models for the association between various drinking patterns and hepatic 
steatosis (LPR ≤ 0.33), overall and by metabolic syndrome 
For continuous alcohol use behaviors, odds ratios are modeled per standard deviation increase in the continuous independent variable.  
Model 1 is adjusted for age, sex, cohort, smoking, physical activity, education, and income.  
Model 2 is adjusted for Model 1, BMI and the components of the metabolic syndrome (waist circumference, low HDL-c, high 
triglycerides, elevated blood pressure, or impaired fasting glucose).  




Characteristics of the study sample, by beverage type 
As a secondary analysis, we evaluated the characteristics of the study sample according 
to alcoholic beverage subtype (beer, wine, liquor/sprit, or mixed type) (Table 3). Over 
half of the participants reported either primary beer drinking (n=575) or primary wine 
drinking (n=809) behavior. Participants who primarily consume beer were younger, less 
frequently women, more frequently current smokers, and less frequently reported the top 
education or income categories. Beer consumers also generally had more cardiometabolic 
risk factors and a higher prevalence of hepatic steatosis compared to wine consumers. 
The pattern of alcohol use also differed for beer and wine consumers with beer 
consumers drinking on average more alcoholic beverages a week, while reporting a 
higher maximum of drinks in 24 hours, and more frequently engaging in binge drinking 
















Age (years) ± SD 44.8±7.8 50.5±9.3 52.1±11.5 47.5±8.8 49.7±9.5 52.9±11.0 
Women, n (%)  102 (17.7%) 544 (67.2%) 120 (51.8%) 51 (45.5%) 51 (54.3%) 377 (59.3%) 
Third Generation, n (%)   488 (84.9%) 541 (66.9%) 149 (59.8%) 80 (71.4%) 61 (64.9%) 368 (57.8%) 
Current smoking use, n (%) 82 (14.3%) 62 (7.7%) 54 (21.7%) 7 (6.3%) 7 (7.5%) 74 (11.6%) 
Physical activity index ± SD 38.5±8.6 36.7±5.9 37.4±7.7 36.9±5.4 36.9±76.4 37.9±7.3 
Education, n (%)       
    Some high school 6 (1%) 9 (1.1%) 4 (1.6%) 0 3 (3.2%) 15 (2.4%) 
    High school graduate 107 (18.6%) 111 (13.7%) 53 (21.3%) 21 (18.8%) 17 (18.1%) 193 (30.4%) 
       Some college 172 (29.9%) 230 (28.4%) 99 (39.8%) 28 (25.0%) 28 (29.8%) 198 (31.1%) 
    College graduate  198 (34.4%) 252 (31.2%) 48 (19.3%) 40 (35.7%) 27 (28.7%) 128 (20.1%) 
    Graduate degree 92 (16%) 207 (25.6%) 45 (18.1%) 23 (20.5%) 19 (20.2%) 102 (16.0%) 
Income*, n (%)       
    <$12,000/yr 2 (0.4%) 5 (0.6%) 0 14 (1.9%) 0 14 (2.2%) 
    $12,000-24,999/yr 16 (2.8%) 14 (1.7%) 3 (2.7%) 36 (4.8%) 4 (4.3%) 33 (5.2%) 
    $25,000-49,999/yr  93 (16.2%) 116 (14.3%) 16 (14.3%) 166 (22.2%) 20 (21.3%) 150 (23.6%) 
    $50,000-74,999/yr 128 (22.3%) 164 (20.3%) 24 (21.4%) 193 (25.8%) 15 (16.0%) 169 (26.6%) 
    $75,000-100,000/yr 147 (25.6%) 173 (21.4%) 31 (27.7%) 172 (23.0%) 23 (24.5%) 141 (22.2%) 
     >$100,000/yr 189 (32.9%) 337 (41.7%) 38 (33.9%) 167 (22.3%) 32 (34.0%) 129 (20.3%) 
BMI (kg/m2) ± SD 27.7±4.8 26.3±4.9 28.4±5.5 26.8±5.0 27.7±4.7 28.3±5.8 
Waist circumference (inches) 
± SD 38.3±4.9 36.5±5.4 39.3±6.0 36.7±5.7 38.1±5.07 38.6±6.1 
Low HDL cholesterol, n (%) 158 (27.5%) 202 (25.0%) 31 (27.7%) 267 (35.7%) 21 (22.3%) 236 (37.1%) 




Elevated blood pressure, n 
(%) 133 (23.1%) 214 (26.5%) 15 (13.4%) 219 (29.3%) 18 (19.1%) 204 (32.1%) 
Impaired Fasting glucose, n 
(%) 57 (9.9%) 59 (7.3%) 9 (8.0%) 121 (16.2%) 8 (8.5%) 112 (17.6%) 
Metabolic syndrome**, n 
(%) 104 (18.1%) 131 (16.2%) 14 (12.5%) 192 (25.7%) 15 (16.0%) 178 (28.0%) 
Liver phantom ratio ± SD 0.36±0.06 0.36±0.05 0.35±0.06 0.36±0.04 0.36±0.04 0.35±0.05 
Hepatic steatosis***, n (%) 102 (17.7%) 123 (15.2%) 13 (11.6%) 139 (18.6%) 10 (10.6%) 126 (19.8%) 
Alcohol use patterns       
Alcohol drinks/week ± SD 6.5±4.9 5.1±4.4 5.5±5.2 3.9±5.6 3.5±3.3 0 
Frequency of drinking 
(#drinking days/wk) 3.0±2.0 2.8±2.2 3.0±2.4 1.8±1.6 1.8±1.4 0.2±0.5 
Usual quantify 
drinks/drinking day**** 2.5±2.0 1.7±0.7 2.0±1.1 1.6±0.7 1.9±1.0 0.7±1.4 
Maximum drinks ± SD 4.7±3.1 2.5±1.8 2.6±2.3 2.5±1.6 2.9±2.7 0.18±0.06 
Binge drinking, n (%) 285 (49.6%) 140 (17.3%) 24 (21.4%) 82 (11%) 25 (26.6%) 58 (9.1%) 
Non-drinkers, n (%)       
     Never drinkers 0 0 0 0 0 58 (9.1%) 
     Former drinkers 0 0 0 0 0 415 (65.3%) 
Table 3: Characteristics of Study Sample, by beverage type 
Data are expressed as mean ± standard deviation or number (percentage) unless otherwise noted. BMI: body mass index 





Multivariable-adjusted logistic regression models for the association between various 
drinking patterns and hepatic steatosis, stratified by beverage type 
When stratifying by alcoholic beverage type consumed, we observed a significant 
association between alcohol drinks per week, frequency of alcohol use, maximum drinks 
in 24 hours, and binge drinking behavior and hepatic steatosis among beer drinkers only 
(Table 4). In multivariable-adjusted models, for beer drinkers, the odds of hepatic 
steatosis increased by 34% per SD increase in the number of beer drinks per week 
(Model 2: OR 1.34; 95% CI 1.04, 1.72), by 19% per SD increase in the frequency of 
alcohol use (Model 2: OR 1.19; 95% CI 1.04, 1.35), and by 37% per SD increase in the 
maximum number of drinks consumed (Model 2: OR 1.37; 95% CI 1.06, 1.77). 
Additionally, beer drinkers who reported binge drinking had 2.27 times the odds of 
hepatic steatosis (95% CI 1.27, 4.11) compared to beer drinkers who did not report binge 
drinking. Among Liquor or spirit drinkers, we observed an association between 
frequency of alcohol use and maximum drinks consumed and hepatic steatosis in adjusted 
models. Similar to beer drinkers, liquor or spirit drinkers the odds of hepatic steatosis 
increased by 33% per SD increase in the frequency of alcohol consumed (OR 1.33; 95% 
CI 1.10, 1.60) or by 61% per SD increase in the maximum number of drinks consumed 
(OR 1.61; 95% CI 1.08, 2.41). For wine drinkers (n=809), we observed no associations 
between alcohol use patterns and hepatic steatosis. Results were overall similar when we 
considered continuous LPR as the dependent variable, though the association between 





Table 4: Multivariable-adjusted logistic regression models for the association between various drinking patterns and 
hepatic steatosis (LPR ≤ 0.33), by alcohol type 
 
 
 Beer drinkers (n=575) Wine drinkers (n=809) Spirit drinkers (n=249) 




CI, p value 
OR, 95% 
CI, p value 
OR, 95% 
CI, p value 
OR, 95% 
CI, p value 
OR, 95% 
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OR, 95% 
CI, p value 
OR, 95% 
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Binge drinking          
  No ref ref ref ref ref ref ref ref ref 
  Yes 2.31 (1.38, 3.85); 0.001 
2.27 (1.26,  
4.11); 0.007 
2.27 (1.28,  
4.02); 0.005 












*For continuous alcohol use behaviors, odds ratios are modeled per standard deviation increase in the continuous independent 
variable. Model 1 is adjusted for age, sex, cohort, smoking, physical activity, education, and income.  
Model 2 is adjusted for Model 1, BMI and the components of the metabolic syndrome (waist circumference, low HDL-c, high 
triglycerides, elevated blood pressure, or impaired fasting glucose).  







We performed a sensitivity limiting the sample to Third Generation Cohort participants 
only (n=1687). Overall, results were similar among Third Generation Cohort participants 
for the association between alcohol use patterns and both hepatic steatosis (A.4) and 






Despite excluding participants based on the recommended threshold for significant 
alcohol use of > 14 drinks per day for women and > 21 drinks per day for men15, frequent 
alcohol drinking, consuming alcohol in excess of the US guidelines, and binge drinking 
were relatively common among participants with presumed NAFLD in the FHS. Overall, 
higher number of alcoholic drinks consumed per week, higher frequency of drinking per 
week, and a higher maximum number of drinks consumed in 24 hours were all associated 
with hepatic steatosis, even after adjusting for BMI and metabolic syndrome. When we 
considered the alcoholic beverage type usually consumed, beer drinkers, particularly 
those reporting binge drinking beer, had an increased odds of hepatic steatosis, whereas 
there were no associations between alcohol use patterns and hepatic steatosis among 
primary wine drinkers.  
There are currently no recommendations regarding specific drinking patterns and how 
drinking behaviors may impact liver fat in patients with NAFLD. The in-depth 
examination of associations between various alcohol use patterns with objectively 
measured hepatic steatosis allow us to offer insights that prior studies have been unable to 
provide.  
To reduce the risk of alcohol related harms, the US Dietary Guidelines for Americans 
recommends that if alcohol is consumed, women should not drink more than 1 drink and 
men should not drink more than 2 drinks per drinking day.19 In our study, we observed 
frequent alcohol consumption above the US guidelines in both women and men with 




with hepatic steatosis. We did, however, observe an association between higher 
maximum drinks consumed in 24 hours and hepatic steatosis. Most adults in the US who 
drink do not drink every day, so the calculating the average number of drinks consumed 
over a week does not account for the number of alcoholic drinks consumed on drinking 
days or the maximum number of alcoholic drinks consumed in 1 day.26,27 Our results 
suggest that considering the maximum number of drinks consumed in a 24 hour period 
may contribute to hepatic steatosis, though additional prospective studies are needed.  
We also observed frequent binge drinking behavior among participants with 
presumed NAFLD in our sample. Similarly, in the Coronary Artery Risk Development in 
Young Adults Study, binge drinking behavior occurring in 27.7% participants with 
NAFLD who consumed alcohol.28 Among alcohol users in our sample, binge drinking 
was associated with hepatic steatosis, though results were no longer significant after 
accounting for BMI and metabolic syndrome. Binge drinking behavior represents a 
caloric load and is associated with the metabolic syndrome in prior studies.29 Metabolic 
syndrome is likely at least a partial mediator on the relationship between binge drinking 
and hepatic steatosis since the direct effect of binge drinking on hepatic steatosis was 
attenuated when accounting for metabolic syndrome. Prior studies also suggest an 
interaction between binge drinking and metabolic syndrome such that the risk for 
decompensated liver disease is highest among those with metabolic syndrome who also 
binge drink.30 Similarly, in a prior general population of individuals with ultrasound-
defined liver fat, excess alcohol use was associated with increased mortality among 




syndrome.13 Additional studies are needed to determine how recommendations for 
alcohol use should be tailored for an individual based on the presence of obesity or 
metabolic syndrome.   
Several prior observational studies suggest a protective effect of light or moderate 
alcohol use on hepatic steatosis or more advanced NAFLD histology.2,3,31-35 In contrast, 
we found the odds of hepatic steatosis increased per SD increase in the weekly average 
alcoholic drinks consumed after accounting for multiple covariates. In the absence of a 
randomized controlled study, any protective association between alcohol use and NAFLD 
histology needs to be interpreted with caution for a number of reasons.14,36 First, alcohol 
use is often self-reported and former or infrequent drinkers may be misclassified as non-
drinkers, which often serves as the reference group. This misclassification may bias away 
from the null since the reference group may be composed of former heavy alcohol users 
with advanced liver histology. Additionally, confounding from socio-demographic 
differences between non-drinkers or moderate alcohol drinkers may also partially or 
completely account for the beneficial effects of alcohol. In one study which noted 
improved histology among modest alcohol users with histologically-defined NAFLD, 
modest alcohol users had higher income and education and lower BMI compared to 
lifetime nondrinker drinkers.2 Although income, education, and BMI were accounted for 
in the multivariable model, residual confounding remains possible.2 A recent Mendelian 
randomization study demonstrated no beneficial effect of moderate alcohol use on the 
histologic severity of NAFLD.7 Two subsequent prospective studies have observed less 




of histology9 for moderate alcohol users compared to non-drinkers. 
The eligibility threshold for NAFLD clinical trial candidates which defines significant 
alcohol as >14 drinks per week for women and >21 drinks per week for men over a 2-
year period preceding baseline histologic examination is based on consensus 
recommendations.15,37 Current guidelines recommend using standardized assessments of 
alcohol use during the clinical trial37, such as The Alcohol Use Disorders Identification 
Test38; however, these tools are rarely used to determine study eligibility. Excess alcohol 
is a well-established risk factor for liver-related morbidity and mortality in numerous 
studies. In the Copenhagen City Heart Study, the increased risk of alcohol-related liver 
disease was significant for women consuming 7 to 13 drinks per week and men 
consuming 14 to 27 drinks per week39, though the risk of alcohol-related liver disease 
occurred at a higher alcohol threshold in other studies.40,41 Our results suggest that 
alcohol use is associated with hepatic steatosis even among individuals meeting the 
typical NAFLD clinical trial eligibility thresholds of alcohol use. Alcohol use may 
represent a source of heterogeneity in NAFLD populations and could represent a source 
of bias towards the null for studies of therapies specifically directed towards NAFLD. 
Additional studies are required to determine if more stringent alcohol use thresholds or if 
criteria for defining binge drinking behavior should be adopted into NAFLD clinical trial 
design.     
In our study, we observed many differences between participants based on the typical 
beverage type consumed. In adjusted models, we observed associations between multiple 




associations among primary wine drinkers. Much of the presumed health benefits of 
alcohol are attributed to polyphenols, which are present in wine and, to a lesser extent, 
beer.42 However, although we accounted for socio-demographic factors, BMI, and 
metabolic disease in our adjusted models, it is likely that differences in odds of hepatic 
steatosis between beer and wine drinkers is, at least in part, accounted for by residual 
confounding by other factors.  
There are a number of potential limitations to consider. First, moderate alcohol use is 
not randomly distributed and there will be numerous differences between those with 
hepatic steatosis who consume modest alcohol vs those that abstain. These factors may 
impact the pattern of alcohol use and the severity of liver disease and serve as 
confounders of the association between alcohol and liver fat. Second, by virtue of being a 
cross-sectional, observational study we cannot account for residual confounding, or 
establish temporality of relations. Additionally, alcohol use behavior is self-reported and 
subject to recall bias and non-differential misclassification with systematic under-
reporting of alcohol use by heavy alcohol users. Individuals with CT-defined hepatic 
steatosis in our sample were community-dwellers who may not have received alcohol use 
counseling so our findings may not be generalizable other populations. Finally, since 






Our findings, if confirmed, suggest that multiple patterns of alcohol use are associated 
with hepatic steatosis in middle-aged, community-dwelling adults. Even after excluding 
heavy alcohol users from our sample, alcohol use contributed to liver fat which suggests 
alcohol-related liver fat may be present among individuals presumed to have NAFLD. 
Additional prospective studies are needed to validate our findings and to determine if 
more comprehensive alcohol use screening tools should be used in practice or clinical 





Appendix Table 1: Characteristics of study participants missing income or 
education variables compared to not missing 
 Missing income or 
education (n=405) 
Not missing data 
(n=2475) 
Age (years) ± SD 57.1±10.5 49.8±10.2 
Women, n (%)  233 (57.5%) 1245 (50.3%) 
Third Generation, n (%)   67 (16.5%) 1687 (68.2%) 
Current smoking use, n (%) 42 (10.4%) 286 (11.6%) 
Physical activity index ± SD 37.8±6.6 37.5±7.2 
BMI (kg/m2) ± SD 27.9±5.2 27.4±5.3 
Waist circumference (inches) ± SD 38.5±5.6 37.8±5.6 
Low HDL cholesterol, n (%) 104 (25.7%) 734 (29.7%) 
High Triglycerides, n (%) 120 (29.6%) 640 (25.9%) 
Elevated blood pressure, n (%) 147 (36.3%) 674 (27.2%) 
Impaired Fasting glucose, n (%) 76 (18.8%) 286 (11.6%) 
Metabolic syndrome**, n (%) 109 (26.9%) 516 (20.9%) 
Liver phantom ratio ± SD 0.36±0.05 0.36±0.05 
Hepatic steatosis***, n (%) 73 (18.0%) 433 (17.5%) 
Alcohol use patterns   
Alcohol drinks/week ± SD 3.7±4.6 4.1±4.7 
Frequency of drinking (#drinking days/wk) 2.0±2.4 2.1±2.2 
Usual quantify consumed (drinks/drinking 
day)**** 1.6±1.2 1.7±1.3 
Maximum drinks ± SD 1.5±1.9 2.4±2.6 
Binge drinking, n (%) 25 (6.2%) 577 (23.3%) 
Non-drinkers, n (%)   
     Never drinkers 14 (4.2%) 58 (2.3%) 
     Former drinkers 113 (27.9%) 415 (16.8%) 
   Primary beverage consumed, n (%)    
        Beer 50 (12.4%) 575 (23.2%) 
        Wine 141 (34.8%) 809 (32.7%) 
        Liquor/Spirits 33 (8.2%) 249 (10.1%) 
        Beer and wine 25 (6.2%) 112 (4.5%) 
      Liquor/Spirits and beer or wine 3 (0.7%) 35 (1.4%) 
        Non-drinkers 153 (37.8%) 695 (28.1%) 
Data are expressed as mean ± standard deviation or number (percentage) unless otherwise 
noted. BMI: body mass index 
**Metabolic syndrome defined by ATP III guidelines 
***Hepatic steatosis defined as LPR ≤ 0.33 





Appendix Table 2: Multivariable-adjusted linear regression models for the association between various drinking 
patterns and more liver fat (-LPR), overall and among drinkers only 
 Overall (n=2475) Drinkers only (n=2002) 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Alcohol use pattern* β, 95% CI, p value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β (95% CI); p 
value 
β (95% CI); p 
value 
β (95% CI); p 
value 
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Binge drinking       
  No reference   reference reference reference 











Non-drinkers       
  Never drinkers reference      




0.009); 0.37    
*For continuous alcohol use behaviors, odds ratios are modeled per standard deviation increase in the continuous independent 
variable.  
Model 1 is adjusted for age, sex, cohort, smoking, physical activity, education, and income.  




Appendix Table 3: Multivariable-adjusted linear regression models for the association between various drinking patterns and more liver fat (-LPR), by alcohol 
type 
 Beer drinkers Wine drinkers Spirit drinkers 
 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 
Alcohol use pattern* β, 95% CI, p value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
β, 95% CI, p 
value 
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Appendix Table 4: Multivariable-adjusted logistic regression models for the association between various drinking 
patterns and hepatic steatosis (LPR ≤ 0.33) (Third Generation only) 
 Model 1 Model 2 Model 3 
Alcohol use pattern* AOR, 95% CI p value AOR, 95% CI p value AOR, 95% CI p value 
Alcohol drinks per week  1.06 (0.93,1.20) 0.41 1.17 (1.01, 1.35) 0.04 1.17 (1.01, 1.35) 0.03 
Frequency (drinking days/week) 1.00 (0.94, 1.07) 1.0 1.08 (1.01, 1.17) 0.04 1.08 (1.00, 1.16) 0.04 
Maximum drinks in 24 hours 1.14 (1.00, 1.30) 0.05 1.14 (0.99, 1.32) 0.08 1.12 (0.98, 1.30) 0.11 
Binge drinking       
  No reference  reference  reference  
  Yes 1.12 (0.84, 1.50) 0.43 1.06 (0.76,1.46) 0.74 1.04 (0.75,1.43) 0.82 
Non-drinkers       
  Never drinkers reference  reference  reference  
  Former drinkers 0.41 (0.16, 1.01) 0.08 0.38 (0.14, 1.07) 0.11 0.34 (0.12, 0.92) 0.06 
*For continuous alcohol use behaviors, odds ratios are modeled per standard deviation increase in the 






Appendix Table 5: Multivariable-adjusted linear regression models for the association between various drinking 
patterns and more liver fat (-LPR) (Third generation only)  
 
 Model 1 Model 2 Model 3 
Alcohol use pattern* β (95% CI) p value β (95% CI) p value β (95% CI) p value 
Alcohol drinks per week  0.002 (-0.0008, 0.004) 0.17 0.003 (0.0008, 0.006) 0.009 0.003 (0.0007, 0.005) 0.01 
Frequency (drinking 
days/week) 0.00002 (-0.002, 0.002) 0.98 0.002 (0.00003, 0.005) 0.05 0.002 (-0.0001, 0.004) 0.06 
Maximum drinks in 24 hours 0.002(-0.0002,0.005) 0.08 0.002 (-0.0002, 0.005) 0.07 0.002 (-0.0006, 0.004) 0.14 
Binge drinking       
  No reference  reference  reference  
  Yes 0.004 (-0.001,0.009) 0.15 0.004 (-0.001, 0.009) 0.16 0.003 (-0.002,0.008) 0.31 
Non-drinkers       
  Never drinkers reference  reference  reference  
  Former drinkers -0.013 (-0.033, 0.007) 0.22 -0.009 (-0.028, 0.009) 0.33 -0.12 (-0.030, 0.007) 0.22 
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